Abstract
The great success of targeted biologic therapy against rheumatoid arthritis (RA) in recent years has meant that much research has been devoted to investigating the pathophysiology of osteoarthritis (OA) in the hope of defining novel therapeutic targets. In contrast to RA, with its pannus and erosions, OA has long been thought of as a degenerative disease of cartilage, with secondary bony damage and osteophytes. But in recent years, the importance of the synovium, and in particular the synovial macrophages, in OA, has been highlighted in both in vitro and in vivo studies. This review will discuss the potential of synovial macrophages and their mediators, in particular the proinflammatory cytokines tumour necrosis factor α and interleukin-1, as potential therapeutic targets in OA.
Keywords: Aggrecanase, interleukin-1, matrix metalloproteinase, macrophage, osteoarthritis, synovium, tumour necrosis factor alpha
Current Drug Targets
Title: Activated Synovial Macrophages as Targets for Osteoarthritis Drug Therapy
Volume: 11 Issue: 5
Author(s): Jan Bondeson
Affiliation:
Keywords: Aggrecanase, interleukin-1, matrix metalloproteinase, macrophage, osteoarthritis, synovium, tumour necrosis factor alpha
Abstract: The great success of targeted biologic therapy against rheumatoid arthritis (RA) in recent years has meant that much research has been devoted to investigating the pathophysiology of osteoarthritis (OA) in the hope of defining novel therapeutic targets. In contrast to RA, with its pannus and erosions, OA has long been thought of as a degenerative disease of cartilage, with secondary bony damage and osteophytes. But in recent years, the importance of the synovium, and in particular the synovial macrophages, in OA, has been highlighted in both in vitro and in vivo studies. This review will discuss the potential of synovial macrophages and their mediators, in particular the proinflammatory cytokines tumour necrosis factor α and interleukin-1, as potential therapeutic targets in OA.
Export Options
About this article
Cite this article as:
Bondeson Jan, Activated Synovial Macrophages as Targets for Osteoarthritis Drug Therapy, Current Drug Targets 2010; 11 (5) . https://dx.doi.org/10.2174/138945010791011965
DOI https://dx.doi.org/10.2174/138945010791011965 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Mapping of Pharmacogenetic Regulatory Variation
Current Pharmaceutical Design Osteoblasts and Osteoclasts in Bone Remodeling and Inflammation
Current Drug Targets - Inflammation & Allergy Cytochrome P450 2C8 and Drug Metabolism
Current Topics in Medicinal Chemistry Selected Players in the Inflammation Cascade and Drugs That Target These Inflammation Genes Against Metastasis
Anti-Cancer Agents in Medicinal Chemistry Toll-Like Receptors: Sensor Molecules for Detecting Damage to the Nervous System
Current Protein & Peptide Science Glycoprotein Targeting and Other Applications of Lectins in Biotechnology
Current Protein & Peptide Science ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design Polyunsaturated Fatty Acids in Emerging Psychosis
Current Pharmaceutical Design Subject Index to Volume 2
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents A Review on Rheumatoid Arthritis Interventions and Current Developments
Current Drug Targets Non Peptidic αvβ3 Antagonists: Recent Developments
Current Medicinal Chemistry Destroying RNA as a Therapeutic Approach
Current Medicinal Chemistry CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry A Role for Leptin in the Systemic Inflammatory Response Syndrome (SIRS) and in Immune Response, an Update
Current Medicinal Chemistry Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies
Current Rheumatology Reviews Silencing of Tumor Necrosis Factor Receptor-1 in Human Lung Microvascular Endothelial Cells Using Particle Platforms for siRNA Delivery
Current Drug Targets Ezetimibe; More Than a Low Density Lipoprotein Cholesterol Lowering Drug? An Update After 4 Years
Current Vascular Pharmacology B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Medical Challanges in Inflammatory Bowel Disease: Quo Vadis in Disease Complexity?)
Current Drug Targets